Receipt date: 01/19/2006 <del>10520572 - GAU: 1626</del> Docket No.: Serial No.: 10/520.572 RLL-256.1CIPUS

INFORMATION DISCLOSURE CITATION

Applicants: MEHTA et al.

Filed: 1/7/2005 Rec'd PCT/PTO 19 JAN ZUUS

Group:

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL					CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	A1	2,490,714	12/6/1949	Searle	260	239	
	A2	3,176,019	3/30/1965	Campbell et al.	260	293.4	
	А3	5,001,160	3/19/1991	McPherson et al.	514	255	
	A4	5,164,402	11/17/1992	Brighty	514	300	
	A5	5,281,601	1/25/1994	Cross et al.	514	320	
	A6	5,397,800	3/14/1995	Alker et al.	514	413	
	A7	5,948,792	9/7/1999	Tsuchiya et al.	514	317	
	A8	6,130,232	10/10/2000	Mase et al.	514	318	
	A9	6,174,900	1/16/2001	Okada et al.	514	317	
	A10	6,313,312	11/6/2001	Banks et al.	548	452	

## FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES   NO
B1	CA 2155320	8/19/1993	Canada	C07D	211/68	1
B2	EP 0 325 571	7/26/1989	EPO	C07C	215/54	
B3	EP 0 388 054	9/19/1990	EPO	C07D	207/08	
B4	EP 0 413 455	2/20/1991	EPO	C07D	401/04	
B5	EP 0 613 232	8/31/1994	EPO	H02M	3/335	
B6	EP 0 801 067	10/15/1997	EPO	C07D	453/02	
B7	EP 0 823 423	2/11/1998	EPO	C07D	211/46	
B8	EP 0 863 141	9/9/1998	EPO	C07D	401/06	
В9	GB 940,540	10/30/1963	UK	C07C		

/Susannah Chung/ (07/29/2008) EXAMINER DATE CONSIDERED \*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not

considered. Include copy of this form with next communication to applicant.

FReceipt date: 01/19/2006 10520572 - GAU: 1626 Docket No.: Serial No.: 10/520,572 RLL-256.1CIPUS

INFORMATION DISCLOSURE CITATION

Applicants: MEHTA et al.

Group: Filed: 1/7/2005

B10	JP 135958/1994	5/17/1994	Japan	C07D	333/16
B11	JP 92921/1994	4/5/1994	Japan	C07C	237/20
B12	WO 91/09013	6/27/1991	PCT	C07D	207/08
B13	WO 93/16018	8/19/1993	PCT	C05F	17/02
B14	WO 93/16048	8/19/1993	PCT	C07D	211/26
B15	WO 96/33973	10/31/1996	PCT \	C07D	211/46
B16	WO 97/45414	12/4/1997	PCT	C07D	211/58
B17	WO 98/05641	2/12/1998	PCT	C07D	211/46
B18	WO 98/29402	7/9/1998	PCT	C07D	311/20
B19	WO 98/53814	12/3/1998	PCT	A61K	31/395
B20	WO 01/42212	6/14/2001	PCT	C07D	211/48
B21	WO 01/42213	6/14/2001	PCT	C07D	211/58
B22	WO 01/90081	11/29/2001	PCT	C07D	241/08
B23	WO 02/00652	1/3/2002	PCT	C07D	453/02
B24	WO 02/04402	1/17/2002	PCT	C07C	219/10
B25	WO 02/51841	7/4/2002	PCT	C07D	453/02
B26	WO 02/06241	1/24/2002	PCT	C07D	223/16
B27	WO 02/53564	7/11/2002	PCT	C07D	453/02
B28	WO 04/004629	1/15/2004	PCT	A61K	
B29	WO 04/005252	1/15/2004	PCT	C07D	209/52
B30	WO 04/014363	2/19/2004	PCT	A61K	31/40
B31	WO 04/014853	2/19/2004	PCT	C07D	209/02
B32	WO 04/018422	3/4/2004	PCT	C07D	209/52
B33	WO 04/052857	6/24/2004	PCT	C07D	209/52
B34	WO 04/056767	7/8/2004	PCT	C07D	207/14
· B35	WO 04/056810	7/8/2004	PCT	C07D	405/12
B36	WO 04/056811	7/8/2004	PCT	C07D	405/12

EXAMINER /Susannah Chung/ (07/29/2008) DATE CONSIDERED

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Receipt date: 01/19/2006	Docket No.: RLL-256.1CIPUS	10520572 - GAU: 1626 Serial No.: 10/520,572		
INFORMATION DISCLOSURE CITATION	Applicants: MEHTA et al.			
	Filed: 1/7/2005	Group:		

B37	WO 04/089900	10/21/2004	PCT		C07D	209/52		i	
	OTHER DOCUME	NTS (Inclu	ding Aut	har Titla Data B	ortinant B	acca Eta l		1	
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)									
C1	de Groat and Yoshimura, "Pharmacology of the Lower Urinary Tract", Annual Review of Pharmacology and Toxicology, 41:691-721 (2001)								
C2	Cheng and Prusoff, "Relationship between the inhibition constant (K <sub>1</sub> ) and the concentration of inhibitor which causes 50 per cent inhibition (I <sub>50</sub> ) of an enzymatic reaction", Biochemical Pharmacology, 22:3099-3108 (1973)								
СЗ	Birdsall et al., "Muscarinic receptors: it's a knockout", Trends in Pharmacological Sciences, 22(5):215-219 (2001)								
C4	Brighty et al., "Sy Achiral Diamine",				oicyclo[3.1	.0]hexane,	a Nove	el	
C5		Braish et al., "Construction of the (1a,5a,6a)-6-Amino-3-azabicyclo[3.1.0]hexane Ring System", Synlett, 1100-1102 (1996)							
C6	Chapple, "Muscarinic receptor antagonists in the treatment of overactive bladder", Urology, 55(Suppl. 5A):33-46 (2000)								
C7	Eglen et al., "Muscarinic receptor ligands and their theraputic potential", Current Opinion in Chemical Biology, 3:426-432 (1999)								
C8	Eglen et al., "Theraputic opportunities from muscarinic receptor research", <i>Trends in Pharmacological Sciences</i> , 22(8):409-414 (2001)								
C9	Felder et al., "Theraputic Opportunities for Muscarinic Receptors in the Central Nervous System", Journal of Medicinal Chemistry, 43(23):4333-4353 (2000)								
C10	Grover et al., "Chiral Mandelic Acid Template Provides a Highly Practical Solution for (S)- Oxybutynin Synthesis", Journal of Organic Chemistry, 65:6283-6287 (2000)								
C11	Shacklett and Smith, "The Preparation of Substituted Benzilic Acids", Journal of the American Chemical Society, 75:2654-2657 (1953)								
C12	Sagara et al., "Cyclohexylmethylpiperidinyltriphenylpropioamide: A Selective Muscarinic M <sub>3</sub> Antagonist Discriminating against the Other Receptor Subtypes", <i>Journal of Medicinal Chemistry</i> , 45:984-987 (2002)								
C13	Nkpa and Chedekel, "Mechanistic Studies on the Addition of Cysteine to 3,4- Dihydroxyphenylalanine", <i>Journal of Organic Chemistry</i> , 46:213-215 (1981)								
C14	Kadin and Canno Activity. II", Journ	n, "Esters c	f N-Meth	yl-3-hydroxypipe	ridine Hav			etic	
C15	Broadley and Kell 193 (2001)					ists", Mole	cules, <u>6</u>	:142-	

EXAMINER	/Susannah Chung/ (07/29/2008)	DATE CONSIDERED					
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not							

considered. Include copy of this form with next communication to applicant.

lèceipt date: 01/19/2006		10520572 - GAU: 1626 Serial No.: 10/520,572
INFORMATION DISCLOSURE CITATION	Applicants: MEHTA et al	

Filed: 1/7/2005

Group:

Moriva et al., "Affinity Profiles of Various Muscarinic Antagonists for Cloned Human C16 Muscarinic Acetylcholine Receptor (mAChR) Subtypes and mAChRs in Rat Heart and Submandibular Gland", Life Sciences, 64(25):2351-2358 (1999) Kubo et al., "Cloning, sequencing and expression of complementary DNA encoding the C17 muscarinic acetylcholine receptor", Nature, 323(2):411-416 (1986) Bonner et al., "Identification of a Family of Muscarinic Acetylcholine Receptor Genes". C18 Science, 237:527-531 (1987) Steers, "The future direction of neuro-urology drug research", Current Opinion in CPNS C19 Investigational Drugs, 2(3):268-282 Steers, Barrot, Wein, "Voiding dysfunction: diagnosis classification and management", In: C20 Adult and Pediatric Urology, ed. Gillenwater, Grayhack, Howards, Duckett. Mosby, St. Louis, MO: 1220-1325, 3rd edition (1996) Weinstock et al., "A General, One-Step Synthesis of α-keto Esters", Synthetic C21 Communications, 11(12):943-946 (1981) C22 Vogel's textbook, "Practical Organic Chemistry" 1046-1047 (5th Ed.) C23 "Design of prodrugs", ed. H. Bundgaard, Elsevier (1985)

FYAMINER DATE CONSIDERED /Susannah Chung/ (07/29/2008) \*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.